Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. 1997

X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-6082, USA.

CD4 functions as a major T-cell surface receptor for human immunodeficiency virus by binding the human immunodeficiency virus type 1 (HIV-1) envelope protein gp120 with relatively high affinity. We have developed constrained aromatically modified analogs of the secondary structures of the first domain of CD4 in order to analyze surfaces involved in binding of gp120. Complementarity determining-like regions (CDRs) of the D1 domain of CD4 were reproduced as synthetic aromatically modified exocyclic (AMEs) forms. The exocyclic CDR3.AME(82-89), derived from the CDR3 (residues 82-89) region of CD4 D1 domain, specifically inhibited binding of recombinant gp120 to both recombinant soluble CD4, and CD4+ Jurkat cells, and blocked syncytium formation and virus particle production caused by HIV-1 infection. We have previously shown that the CDR3.AME analog binds to the CD4 CDR3 region and creates a disabled CD4 heterodimer. We propose that the AME prevents the formation of an essential homodimeric surface needed for efficient HIV binding. Additionally the disabled CD4 receptor may be less able to signal the cell to allow HIV replication and HIV infection. Such compounds may represent a new receptor specific approach to modulate biological functions.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
November 1992, Journal of virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
August 2004, Virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
March 2003, Clinical and experimental immunology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
March 1999, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
May 2002, Journal of virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
August 1993, AIDS research and human retroviruses,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
July 2000, Journal of virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
May 2003, Journal of medical virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
February 1997, Journal of virology,
X Zhang, and M Gaubin, and L Briant, and V Srikantan, and R Murali, and U Saragovi, and D Weiner, and C Devaux, and M Autiero, and D Piatier-Tonneau, and M I Greene
January 1992, Journal of virology,
Copied contents to your clipboard!